Urodynamics in the evaluation of overactive bladder

Current Urology Reports

Volumn 11, Issue 5, 2010, Pages 343-347

  Rovner, Eric S ^a   Goudelocke, Colin M ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antimuscarinics; Botulinum toxin A; Detrusor overactivity; Motor; Overactive bladder; Sacral neuromodulation; Sensory; Urgency; Urgency incontinence; Urodynamics

Indexed keywords

BOTULINUM TOXIN A; CAPSAICIN; FESOTERODINE; LIDOCAINE; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; TOLTERODINE;

CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HUMAN; MOTOR DYSFUNCTION; NEUROMODULATION; NONHUMAN; OVERACTIVE BLADDER; PATIENT ASSESSMENT; PATIENT MONITORING; REVIEW; SELF REPORT; SENSORY DYSFUNCTION; TREATMENT INDICATION; TREATMENT PLANNING; URGE INCONTINENCE; URINARY URGENCY; URODYNAMICS;

HUMANS; URINARY BLADDER, OVERACTIVE; URODYNAMICS;

EID: 77955985073     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-010-0130-8     Document Type: Review

References (28)

1. P Abrams L Cardozo M Fall, et al. 2002 The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society Am J Obstet Gynecol 187 116 126 10.1067/mob.2002.125704 12114899
2. P Abrams 2003 Describing bladder storage function: overactive bladder syndrome and detrusor overactivity Urology 62 5 Suppl 2 28 37 10.1016/j.urology.2003.09.050 14662404
3. VW Nitti ES Rovner T Bavendam 2010 Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity BJU Int 105 1268 1275 10.1111/j.1464-410X.2009.09037.x 1:CAS:528:DC%2BC3cXms1OlsL4%3D 19889062 In this report from a randomized placebo-controlled trial of fesoterodine, response of overactive bladder symptoms to antimuscarinic treatment was not dependent on finding of detrusor overactivity on pretreatment urodynamics
4. JG Malone-Lee S Al-Buheissi 2009 Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study BJU Int 103 931 937 10.1111/j.1464-410X.2009.08361.x 19281469 In this trial of tolterodine-ER, patients were stratified into groups of patients with and without pretreatment detrusor overactivity. Presence of detrusor overactivity could not be used to predict response to treatment or placebo, suggesting that urodynamic assessment of detrusor overactivity may not be required before treatment of overactive bladder with antimuscarinic therapy
5. R Eric 2010 Urodynamic results and clinical outcomes with intravesical botulinum toxin a (onabotuliumtoxina) in a randomized, placebo-controlled, dose-finding study in idiopathic overactive bladder J Urol 183 4 Suppl e591 e592
6. MM South AA Romero MG Jamison, et al. 2007 Detrusor overactivity does not predict outcome of sacral neuromodulation test stimulation Int Urogynecol J Pelvic Floor Dysfunct 18 1395 1398 10.1007/s00192-007-0351-7 17364132 This retrospective review found that patients characterized as responders to test neurostimulation for overactive bladder were not more likely to have detrusor overactivity on pretreatment urodynamics than those who failed to respond to a test stimulation, suggesting that detrusor overactivity is not a requirement for test neurostimulation
7. GA Digesu V Khullar L Cardozo S Salvatore 2003 Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn 22 105 108 10.1002/nau.10099 12579626 Published erratum appears in Neurourol Urodyn 2003, 22:356
8. H Hashim P Abrams 2006 Is the bladder a reliable witness for predicting detrusor overactivity? J Urol 175 191 194 10.1016/S0022-5347(05)00067-4 1:STN:280:DC%2BD28%2FitVGltQ%3D%3D 16406907
9. L Lowenstein T Pham S Abbasy, et al. 2009 Observations relating to urinary sensation during detrusor overactivity Neurourol Urodyn 28 497 500 10.1002/nau.20680 19090593
10. A Renganathan R Cartwright L Cardozo, et al. 2009 Quality control in urodynamics: Analysis of an international multi-center study Neurourol Urodyn 28 380 384 10.1002/nau.20679 19090592
11. K Heslington P Hilton 1996 Ambulatory monitoring and conventional cystometry in asymptomatic female volunteers Br J Obstet Gynaecol 103 434 441 1:STN:280:DyaK283hs1yktQ%3D%3D 8624316
12. SR Lee HJ Kim A Kim JH Kim 2010 Overactive bladder is not only overactive but also hypersensitive Urology 75 1053 1059 10.1016/j.urology.2009.10.045 20092879
13. CH Ho HC Tai HJ Yu 2010 Urodynamic findings in female diabetic patients with and without overactive bladder symptoms Neurourol Urodyn 29 424 427 19283863
14. ML Guralnick G Grimsby M Liss, et al. 2010 Objective differences between overactive bladder patients with and without urodynamically proven detrusor overactivity Int Urogynecol J Pelvic Floor Dysfunct 21 325 329 10.1007/s00192-009-1030-7 19907912
15. AF Brading 1997 A myogenic basis for the overactive bladder Urology 50 6A Suppl 57 67 10.1016/S0090-4295(97)00591-8 1:STN:280:DyaK1c%2FovVWmug%3D%3D 9426752
16. C Maake M Landman X Wang, et al. 2006 Expression of smoothelin in the normal and the overactive human bladder J Urol 175 1152 1157 10.1016/S0022-5347(05)00315-0 1:CAS:528:DC%2BD28XitFSit7o%3D 16469643
17. DE Rapp MB Lyon GT Bales SP Cook 2005 A role for the P2X receptor in urinary tract physiology and in the pathophysiology of urinary dysfunction Eur Urol 48 303 308 10.1016/j.eururo.2005.04.019 1:CAS:528:DC%2BD2MXovVOrtrY%3D 15963632
18. AP Ford JR Gever PA Nunn, et al. 2006 Purinoceptors as therapeutic targets for lower urinary tract dysfunction Br J Pharmacol 147 Suppl 2 S132 S143 10.1038/sj.bjp.0706637 1:CAS:528:DC%2BD28XhtFGqsbo%3D 16465177
19. K De Laet S De Wachter JJ Wyndaele 2006 Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics Neurourol Urodyn 25 156 161 10.1002/nau.20208 16372316
20. K Iijima S De Wachter JJ Wyndaele 2007 Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve Eur Urol 52 842 847 10.1016/j.eururo.2007.02.057 17360104
21. S Boy B Schurch U Mehnert, et al. 2007 The effects of tolterodine on bladder-filling sensations and perception thresholds to intravesical electrical stimulation: method and initial results BJU Int 100 574 578 10.1111/j.1464-410X. 2007.06903.x 1:CAS:528:DC%2BD2sXhtVynsLbL 17669142
22. SM Finney KE Andersson JI Gillespie LH Stewart 2006 Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int 98 503 507 10.1111/j.1464-410X.2006.06258.x 1:CAS:528:DC%2BD28XhtVWru7rO 16925744
23. DC Panayi P Tekkis R Fernando V Khullar 2010 Is the beneficial effect of antimuscarinics related to motor or sensory changes in the bladder? Int Urogynecol J Pelvic Floor Dysfunct 21 841 845 10.1007/s00192-010-1123-3 20349178
24. K Juszczak A Ziomber M Wyczolkowski PJ Thor 2009 Urodynamic effects of the bladder C-fiber afferent activity modulation in chronic model of overactive bladder in rats J Physiol Pharmacol 60 85 91 1:CAS:528:DC%2BC3cXht1Witr4%3D 20065501
25. Goldman HB, Vasavada SP: Female urology: a practical clinical guide. Totowa, NJ: Humana Press; 2007.
26. A Sahai MS Khan N Le Gall, et al. 2008 Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder Urology 71 455 459 10.1016/j.urology.2007.11.039 18342186
27. BL Cohen P Barboglio D Rodriguez AE Gousse 2009 Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units Neurourol Urodyn 28 205 208 10.1002/nau.20611 1:CAS:528:DC%2BD1MXltFCgu78%3D 19058190
28. PM Groenendijk AA Lycklama a Nyeholt JP Heesakkers, et al. 2008 Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence BJU Int 101 325 329 10.1111/j.1464-410X.2007.07258.x 18070199 This study of patients with neurostimulator placement for overactive bladder found that even those patients with pretreatment detrusor overactivity on urodynamics who had resolution of their detrusor overactivity 6 months later while the stimulator was on had no difference in rates of improvement in symptoms over those patients who had no resolution of detrusor overactivity